XML 31 R21.htm IDEA: XBRL DOCUMENT
v3.21.4

Note 14 - Warrants | 6 Months Ended
--- | ---
Oct. 31, 2021
Note 14 - Warrants |
Note 14 - Warrants | Note 14 - Warrants In October 2020, the Company issued five-year warrants to purchase a total of 399,998 shares in connection with the issuance of $600,000 of convertible notes. The warrants have an initial exercise price of $1.50 which may be reduced to a 25% discount of the price per share of Common Stock offered in a future qualified offering. The warrants were valued at $267,999 using the multinominal lattice model and are considered derivative liabilities under ASC 815-40. The value of the warrants was included in the determination of the initial accounting for the financing including the calculation of the derivative liability and related expense. In January 2021, the Company issued five-year warrants to purchase a total of 675,000 shares in connection with the issuance of $500,000 of convertible notes. The warrants have an initial exercise price of $1.50 which may be reduced to a 25% discount of the price per share of Common Stock offered in a future qualified offering. The warrants were valued at $2,870,666 using the multinominal lattice model and are considered derivative liabilities under ASC 815-40. The value of the warrants was included in the determination of the initial accounting for the financing including the calculation of the derivative liability and related expense. In March and April 2021, we received $201,249 in connection with the exercise of 201,666 warrants which had been issued in October 2020 and January 2021 as part of the convertible note financings described in note 10. Since these exercises resulted in the elimination of the derivative liability in the warrants, the derivative liability was reduced by $694,305 with a corresponding increase in additional paid in capital. In May 2021, the Company issued warrants to purchase 200,000 shares of common stock to the placement agent of its common stock offering. The warrants have a five year term and an exercise price of $5.00. In June 2021, we received $99,999 in connection with the exercise of 66,666 warrants which had been issued in October 2020 as part of the convertible note financings described in Note 6. Since these exercises resulted in the elimination of the derivative liability in the warrants, the derivative liability was reduced by $163,141 with a corresponding increase in additional paid in capital. In July 2021, the Company issued warrants to purchase 533,333 shares of common stock to the placement agent of its common stock offering. The warrants have a five year term and an exercise price of $5.625. The following table summarizes the changes in warrants outstanding since April 30, 2020.
|  | Number of Shares |  | Weighted-average Exercise Price per Share |  | Weighted-average Remaining Contractual Term (in years) |  | Aggregate Intrinsic Value
Balance as of April 30, 2020 | — |  |  |  | — |  |  |  | — |  |  |  | — |
Granted |  |  | 1,074,998 |  |  | $ | 1.50 |  |  |  |  |  |  |  |  |
Exercised |  |  | (201,666 | ) |  |  | 1.50 |  |  |  |  |  |  |  |  |
Outstanding as of April 30, 2021 | 873,332 |  |  |  | 1.50 |  |  |  | 4.62 |  |  | $ | 2,218,263 |
Granted | 733,333 |  |  |  | 5.45 |  |  |  |  |  |  |  |  |
Exercised | (66,666 | ) |  |  | 1.50 |  |  |  |  |  |  |  |  |
Outstanding at October 31, 2021 | 1,539,999 |  |  | $ | 3.38 |  |  |  | 4.38 |  |  | $ | 2,387,731 |

X
- References No definition available. + Details
Name: | RCAT_DisclosureNote14WarrantsAbstract
Namespace Prefix: | RCAT_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | RCAT_WarrantsDisclosureTextBlock
Namespace Prefix: | RCAT_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration